Singapore Institute of Advanced Medicine Holdings Ltd.

Singapore Institute of Advanced Medicine Holdings Ltd.

SSGX:9G2
0.03
SGD
+0.00
(-3.70%)
51.72MMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
0.01
0.01
0.02
0.02
0.01
0.01
- -
Basic EPS, GAAP
-0.01
-0.01
-0.02
-0.04
-0.02
-0.02
- -
Free Cash Flow per Basic Share
-0.01
-0.01
-0.02
-0.02
-0.01
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.05
0.05
0.04
0.07
0.05
0.03
0.03
Tangible Book Value per Share
0.05
0.05
0.04
0.07
0.05
0.03
0.03
Basic Weighted Avg Shares
1,077
1,077
1,077
879
1,052
1,191
1,241
Sales/Revenue/Turnover
13
14
16
17
16
16
- -
Operating Margin (%)
-69.93
-98.81
-87.39
-127.69
-139.94
-128.09
- -
Depreciation Expense
5
5
6
12
12
11
- -
Net Income, GAAP
-9
-12
-18
-37
-26
-24
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-72.38
-89.98
-111.32
-224.95
-166.53
-152.04
- -
Working Capital
-18
-30
-39
-8
-12
-17
-17
LT Debt
77
66
54
40
47
39
39
Total Equity
59
54
45
82
56
53
53
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-21.95
-36.52
-59.12
-38.08
-44.03
- -

Capital Structure

SGD

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
11
19
22
LT Borrowings
17
11
11
LT Finance Leases
30
29
28
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,316
1,316
1,724
Market Capitalization
85
50
52

Working Capital

SGD

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
6
5
18
Cash, Cash Equivalents & STI
4
2
15
Accounts Receivable, Net
2
2
2
Inventories
- -
- -
- -
Total Current Liabilities
23
33
35
Payables & Accruals
- -
- -
- -
ST Debt
11
19
22
Deferred Revenue
- -
- -
- -

Growth Rates

SGD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
3.92%
-4.89%
Free Cash Flow
- -
-0.31%
-61.63%
Net Income, GAAP
- -
29.35%
-8.65%
Sales/Revenue/Turnover
- -
4.28%
0.05%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SGD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
17
2025
- -
- -
4
4
16
2026
- -
- -
4
4
16

Quarterly Earnings Per Share

SGD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.04
2025
- -
- -
-0.01
-0.01
-0.02
2026
- -
- -
- -
-0.01
-0.02

Quarterly Dividends Per Share

SGD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Shih Kien Djeng
Full Time Employees
104
Sector
Health services
Industry
Hospital/Nursing management
Address
No. 02-01, 1 Biopolis Drive Singapore CE Singapore 138622
IPO Date
Feb 16, 2024
Business
Singapore Institute of Advanced Medicine Holdings Ltd. (SAM Holdings) is a Singapore-based investment holding company that provides advanced medical diagnostics, treatments, radiation therapy, and medical oncology services primarily focused on cancer care and related conditions. Founded in 2011 and headquartered at 1 Biopolis Drive, #02-01 Amnios, Singapore 138622, the company operates through subsidiaries including Asia HealthPartners, Advanced Medicine Imaging, and Proton Therapy SG, with facilities in Biopolis, Orchard Road's Lucky Plaza, and Mount Elizabeth Orchard Medical Center. Its core products and services encompass medical diagnostics and treatments such as cancer-related diagnostics, theranostics, general diagnostics, health screening, aesthetic services, general practice, plastic surgery, endoscopy, and imaging modalities including MRI, CT, PET/CT, X-ray, mammography, and ultrasound; radiation therapy offerings include proton beam therapy, photon radiation therapy, stereotactic radiosurgery, and medical oncology; as well as nuclear medicine services supported by an in-house radiopharmaceutical laboratory for on-demand production. The company serves patients across Singapore, targeting complex medical challenges in oncology, neurodegenerative, and cardiovascular diseases through a multidisciplinary team of specialists and cutting-edge technologies like those from Philips, Varian, and Siemens. In recent developments, SAM Holdings forged a strategic partnership with EnGeneIC in June 2024 to advance EDV-based cancer therapeutics and theranostics across Asia, including exclusive sales rights and shared profits; signed medical service agreements with Raffles Hospital and collaborates with the National Cancer Centre Singapore on research and drug trials; completed a S$5.24 million debt conversion and S$0.69 million share placement in 2025 to strengthen its balance sheet and pursue new opportunities like rights issues; and fully launched its Biopolis proton therapy center in 2023 following COVID-19 delays, enhancing its comprehensive radiotherapy capabilities.